secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2021-11-01T23:59:59+00:00
Accession:  0000950170-21-002562
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass reports CTX-009 Phase 2a ORR 29% in BTC; proposes public offering and Nasdaq uplist
--------------------------------------------------------------------------------

- CTX-009 Phase 2a in biliary tract cancer met criteria to advance; 5 partial responses in 17 patients (ORR 29%), 100% clinical benefit rate.
- Compass plans to submit US IND this quarter, initiate Phase 2 study in Q2 2022.
- Preliminary cash $25.5M as of Sep 30, 2021; proposes underwritten public offering of common stock plus 15% option for underwriters.
- Common stock approved for Nasdaq Capital Market listing under symbol CMPX, subject to offering pricing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000095017021002562/0000950170-21-002562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000095017021002562/cmpx-20211101.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-002562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer